These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 19812735

  • 1. Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.
    Zhao JH, Liu HL, Lin HY, Huang CH, Fang HW, Chen SS, Ho Y, Tsai WB, Chen WY.
    Perspect Medicin Chem; 2007 Dec 11; 1():39-48. PubMed ID: 19812735
    [Abstract] [Full Text] [Related]

  • 2. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK, Paul S.
    FEBS J; 2006 Apr 11; 273(7):1331-49. PubMed ID: 16689923
    [Abstract] [Full Text] [Related]

  • 3. Protein conformational diseases: from mechanisms to drug designs.
    Lin JC, Liu HL.
    Curr Drug Discov Technol; 2006 Jun 11; 3(2):145-53. PubMed ID: 16925522
    [Abstract] [Full Text] [Related]

  • 4. Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly.
    Hervás R, Oroz J.
    Int J Mol Sci; 2020 Dec 02; 21(23):. PubMed ID: 33276458
    [Abstract] [Full Text] [Related]

  • 5. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A.
    Int J Biol Macromol; 2019 Jun 15; 131():396-411. PubMed ID: 30853582
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of disease II: cellular protein quality control.
    Outeiro TF, Tetzlaff J.
    Semin Pediatr Neurol; 2007 Mar 15; 14(1):15-25. PubMed ID: 17331880
    [Abstract] [Full Text] [Related]

  • 7. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
    Zaman M, Khan AN, Wahiduzzaman, Zakariya SM, Khan RH.
    Int J Biol Macromol; 2019 Aug 01; 134():1022-1037. PubMed ID: 31128177
    [Abstract] [Full Text] [Related]

  • 8. New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies.
    Foguel D, Silva JL.
    Biochemistry; 2004 Sep 14; 43(36):11361-70. PubMed ID: 15350123
    [Abstract] [Full Text] [Related]

  • 9. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y, Popiel HA.
    Curr Pharm Des; 2008 Sep 14; 14(30):3267-79. PubMed ID: 19075705
    [Abstract] [Full Text] [Related]

  • 10. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
    Naeem A, Fazili NA.
    Cell Biochem Biophys; 2011 Nov 14; 61(2):237-50. PubMed ID: 21573992
    [Abstract] [Full Text] [Related]

  • 11. [Neurodegenerative conformational disease and its molecular bases].
    Li WW, Cai DF, Ren HM.
    Sheng Li Ke Xue Jin Zhan; 2006 Apr 14; 37(2):97-102. PubMed ID: 16850610
    [Abstract] [Full Text] [Related]

  • 12. The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases.
    Lackie RE, Maciejewski A, Ostapchenko VG, Marques-Lopes J, Choy WY, Duennwald ML, Prado VF, Prado MAM.
    Front Neurosci; 2017 Apr 14; 11():254. PubMed ID: 28559789
    [Abstract] [Full Text] [Related]

  • 13. Protein Quality Control by Molecular Chaperones in Neurodegeneration.
    Ciechanover A, Kwon YT.
    Front Neurosci; 2017 Apr 14; 11():185. PubMed ID: 28428740
    [Abstract] [Full Text] [Related]

  • 14. Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders.
    Bose S, Cho J.
    Ageing Res Rev; 2017 May 14; 35():155-175. PubMed ID: 27702699
    [Abstract] [Full Text] [Related]

  • 15. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC.
    Ann N Y Acad Sci; 2005 Dec 14; 1066():181-221. PubMed ID: 16533927
    [Abstract] [Full Text] [Related]

  • 16. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y.
    Rinsho Shinkeigaku; 2009 Nov 14; 49(11):913-6. PubMed ID: 20030247
    [Abstract] [Full Text] [Related]

  • 17. Chemical chaperones: mechanisms of action and potential use.
    Papp E, Csermely P.
    Handb Exp Pharmacol; 2006 Nov 14; (172):405-16. PubMed ID: 16610368
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.